6 Undervalued Biotechnology & Medical Research Stocks for Friday, May 31
Discover the top 6 undervalued Biotechnology & Medical Research stocks for Friday, May 31 based on AAII’s Stock Grades.Eunice Kim
Stock Evaluator: Adial Pharmaceuticals, Inc. (ADIL)
Adial Pharmaceuticals, Inc. ADIL
$4.68
-0.53
-10.17%
September 18, 2026 2:16:14 PM
EST
Volume: 51,626
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Commentary & Analysis
Why Adial Pharmaceuticals Inc’s (ADIL) Stock Is Up 128.10%
As of Wednesday, February 28, Adial Pharmaceuticals Inc’s ADIL share price has surged by 128.10%, which has investors questioning if this is right time to sell.Jenna Brashear
Is Adial Pharmaceuticals Inc (ADIL) a Good Investment?
Learn more about Adial Pharmaceuticals Inc’s (ADIL) stock grades for Growth, Momentum and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Charles Griswold
Financial Summary
| Share Statistics | ADIL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $13.7 | $589.9 | 8% |
|
| Shares Out (Mil) | 2.6 | 43.1 | 9% |
|
| Institutional Ownership | 49.1% | 83.7% | 23% |
|
| Float (Mil) | 1.8 | 45.1 | 5% |
|
| Beta | 1.39 | 0.73 | 79% |
|
| Avg Daily Volume (000s) | 47 | 300 | 28% |
|
| Price Change (52-week) |
(39.9%) | 65.3% | 21% |
|
| Growth | ADIL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | 6.0% | (1.4%) | 49% |
|
| EPS (5yr) | 53.5% | 15.1% | 94 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 15.2% | (15.0%) | 73% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 1 | 2 | |
| Current EPS | ($2.575) | ($1.050) | ($7.450) | |
| Month Ago EPS | ($2.575) | ($1.050) | ($7.450) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($5.000) | na | ($14.250) | |
| Year/Year Chg | (87.0%) | (91.2%) | (94.5%) | |
| Financials | ADIL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $317 | na |
|
| Net Income (TTM) (Mil) | ($58) | ($11) | 15% |
|
| EPS (TTM) | ($22.012) | ($0.700) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($11) | ($6) | 19% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 0% |
|
| Enterprise Value (Q1) (Mil) | $29 | $508 | 13% |
|
| Valuation | ADIL | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.51 | na |
|
| P/E | na | 17.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ADIL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 2.5% | na |
|
| ROA | (322.1%) | (22.5%) | 1% |
|
| ROE | 352.6% | (21.8%) | 99% |
|
| Liabilities to Assets | 99.5% | 32.5% | 94% |
|
| F-Score | 2 | 3 | 7% |
|
Adial Pharmaceuticals, Inc. did not pass any screens on 9/17/2026.
